Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.